scholarly journals Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

2022 ◽  
Author(s):  
Sotaro Chikamatsu ◽  
Masaki Shiota ◽  
Shigetomo Yamada ◽  
Leandro Blas ◽  
Takashi Matsumoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Stratification ◽  
Prognostic Significance ◽  
Castration Resistant Prostate Cancer ◽  
Japanese Men ◽  
Castration Resistant

Are there any significant impacts of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer?

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16522-e16522
Author(s):  
Takeo Kosaka ◽  
Hiroshi Hongo ◽  
Ryuichi Mizuno ◽  
Nobuyuki Tanaka ◽  
Toshikazu Takaeda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Significance ◽  
University Hospital ◽  
Castration Resistant Prostate Cancer ◽  
Patient Age ◽  
Oncological Outcomes ◽  
Castration Resistant ◽  
Patient Âgé ◽  
Psa Response ◽  
Treatment Profile

e16522 Background: The correlation of the oncological outcomes of patient age in metastatic castration resistant prostate cancer (mCRPC) patients have not been unclear. Materials and Methods: This study included a total of 56 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic significance of cabazitaxel at Keio University Hospital from 2014 to 2019 were included., focusing on patient age and the correlation of efficacy between docetaxel and cabazitaxel. All patients received cabazitaxel at 20-25 mg/m2 administered intravenously on day 1 of each treatment cycle, together with prednisone 5 mg twice daily. Prophylactic administration of G-CSF was prescribed to all the patients. Results: The median overall survival (OS) periods after the introduction of cabazitaxel was 16.1 months. A 30% PSA response to cabazitaxel was achieved in 5 (50.0%) patients with ≧75 years (n = 10) and 19 (41.3%) patients with less than 75 years (n = 46). There was no significant correlation between the PSA response and patients’ age (p = 0.087). A 30% PSA response to cabazitaxel was achieved in 25 (43.9%) patients. A 30% PSA response to cabazitaxel was achieved in 15 (57.6%) and 10 (33.3%) patients with and without that to docetaxel, respectively. There was no significant correlation of the PSA response between docetaxel and cabazitaxel (p = 0.106). Univariate and multivariate analysis revealed that there were no significant correlation of patient age, the response to prior docetaxel therapyor cycles of docetaxel therapy with shorter OS. Conclusions: These results indicate that the introduction of cabazitaxel for mCRPC patients could result in oncological outcomes without any association with patient’s age and the profiles of previous docetaxel therapy.

Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 157-157
Author(s):  
Howard I. Scher ◽  
Andrew J. Armstrong ◽  
Joseph D. Schonhoft ◽  
Audrey Gill ◽  
Jimmy Zhao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cell ◽  
Validation Cohort ◽  
Prognostic Significance ◽  
Circulating Tumor Cell ◽  
Cancer Center ◽  
Significant Prognostic Factor ◽  
Castration Resistant Prostate Cancer ◽  
Discovery Cohort ◽  
Castration Resistant

157 Background: We evaluated the prognostic significance of circulating tumor cell (CTC) number as determined on the Epic Sciences platform in men with metastatic castration resistant prostate cancer (mCRPC) treated with an androgen receptor signaling inhibitor (ARSI). Methods: A pre-treatment blood sample was collected from men with progressing mCRPC starting either abiraterone or enzalutamide as a 1st, 2nd or 3rd line systemic therapy at Memorial Sloan Kettering Cancer Center (Discovery cohort, N=175) or as a 1st and 2nd line therapy as part of the multi-center PROPHECY trial (NCT02269982) (Validation cohort, N=107). Enumeration was performed on the Epic Sciences platform and associated with overall survival (OS) in the Discovery cohort, and progression-free survival (PFS) and OS in the Validation cohort. Matched blood samples from the Validation cohort were to CTC counts measured on the CellSearch Circulating Tumor Cell kit. Results: In the MSKCC Discovery cohort, CTC count was a statistically significant prognostic factor of OS as a dichotomous (< 3 CTCs/mL versus ≥ 3 CTCs/mL; HR = 1.8, (1.3-3.0, 95% CI)) and as a continuous variable when adjusting for line of therapy, presence of visceral metastases, PSA, lactate-dehydrogenase, and alkaline-phosphatase. The findings were validated in an independent dataset (PROPHECY trial) - (HR (95% CI) = 1.8, (1.1-3.0) for OS and 1.7 (1.1-2.9), for PFS). A strong correlation was observed between CTC counts determined in matched samples on the CellSearch and Epic platforms (r = 0.84). Conclusions: The findings validate the prognostic significance of pretreatment CTC number determined on the Epic Sciences platform for predicting OS in men with progressing mCRPC starting an ARSI.

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

2018 ◽  
Vol 26 (3) ◽  
pp. 426-428 ◽  
Author(s):  
Masaki Shiota ◽  
Ryo Namitome ◽  
Takeshi Kobayashi ◽  
Junichi Inokuchi ◽  
Katsunori Tatsugami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Stratification ◽  
Metastatic Prostate Cancer ◽  
De Novo ◽  
Prognostic Significance ◽  
Japanese Men

scholarly journals Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 780
Author(s):  
Martha Zavridou ◽  
Areti Strati ◽  
Evangelos Bournakis ◽  
Stavroula Smilkou ◽  
Victoria Tserpeli ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
Dna Methylation ◽  
Tumor Cells ◽  
Liquid Biopsy ◽  
Prognostic Significance ◽  
Comparison Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
First Time

Liquid biopsy, based on the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), provides non-invasive real-time monitoring of tumor evolution and therapeutic efficacy. We performed for the first time a direct comparison study on gene expression and DNA methylation markers in CTCs and paired plasma-derived exosomes and evaluated their prognostic significance in metastatic castration resistant prostate cancer. This prospective liquid biopsy (LB) study was based on a group of 62 metastatic castration resistant prostate cancer (mCRPC) patients and 10 healthy donors (HD) as controls. Identical blood draws were used to: (a) enumerate CTC and tumor-derived extracellular vesicles (tdEVs) using CellSearch (CS) and (b) analyze CTCs and paired plasma-derived exosomes at the gene expression and DNA methylation level. CTCs were enumerated using CellSearch in 57/62 patients, with values ranging from 5 to 854 cells/7.5 mL PB. Our results revealed for the first time a significantly higher positivity of gene expression markers (CK-8, CK-18, TWIST1, PSMA, AR-FL, AR-V7, AR-567 and PD-L1 mRNA) in EpCAM-positive CTCs compared to plasma-derived exosomes. GSTP1, RASSF1A and SCHLAFEN were methylated both in CTC and exosomes. In CTCs, Kaplan–Meier analysis revealed that CK-19 (p = 0.009), PSMA (p = 0.001), TWIST1 (p = 0.001) expression and GSTP1 (p = 0.001) methylation were correlated with OS, while in exosomes GSTP1 (p = 0.007) and RASSF1A (p = 0.001) methylation was correlated with OS. Our direct comparison study of CTCs and exosomes at gene expression and DNA methylation level, revealed for the first time a significantly higher positivity in EpCAM-positive CTCs compared to plasma-derived exosomes. Future perspective of this study should be the evaluation of clinical utility of molecular biomarkers in CTCs and exosomes on independent multicentric cohorts with mCRPC patients.

Sign in / Sign up

Export Citation Format

Share Document